Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription coactivator activity	KAT6B SS18 NCOA1 BCL9L NCOA3 EP300 KAT6A BCL9	2.76e-10	303	20	8	GO:0003713
GeneOntologyMolecularFunction	histone acetyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.34e-09	51	20	5	GO:0004402
GeneOntologyMolecularFunction	peptide-lysine-N-acetyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.98e-09	55	20	5	GO:0061733
GeneOntologyMolecularFunction	peptide N-acetyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	3.09e-09	60	20	5	GO:0034212
GeneOntologyMolecularFunction	N-acetyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.18e-08	78	20	5	GO:0008080
GeneOntologyMolecularFunction	transcription coregulator activity	KAT6B SS18 NCOA1 BCL9L NCOA3 EP300 KAT6A BCL9	3.50e-08	562	20	8	GO:0003712
GeneOntologyMolecularFunction	N-acyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	4.60e-08	102	20	5	GO:0016410
GeneOntologyMolecularFunction	acetyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	5.07e-08	104	20	5	GO:0016407
GeneOntologyMolecularFunction	histone H3 acetyltransferase activity	KAT6B EP300 KAT6A	3.88e-07	15	20	3	GO:0010484
GeneOntologyMolecularFunction	histone modifying activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	2.56e-06	229	20	5	GO:0140993
GeneOntologyMolecularFunction	acyltransferase activity, transferring groups other than amino-acyl groups	KAT6B NCOA1 NCOA3 EP300 KAT6A	3.09e-06	238	20	5	GO:0016747
GeneOntologyMolecularFunction	chromatin binding	FOXA2 KAT6B NCOA1 NCOA3 EP300 KAT6A ZIC2	4.70e-06	739	20	7	GO:0003682
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	KAT6B SS18 NCOA1 BCL9L NCOA3 EP300 KAT6A BCL9	8.51e-06	1160	20	8	GO:0030674
GeneOntologyMolecularFunction	molecular adaptor activity	KAT6B SS18 NCOA1 BCL9L NCOA3 EP300 KAT6A BCL9	2.67e-05	1356	20	8	GO:0060090
GeneOntologyMolecularFunction	nuclear receptor coactivator activity	SS18 NCOA1 NCOA3	2.98e-05	61	20	3	GO:0030374
GeneOntologyMolecularFunction	histone H3K14 acetyltransferase activity	KAT6B KAT6A	3.42e-05	9	20	2	GO:0036408
GeneOntologyMolecularFunction	peroxisome proliferator activated receptor binding	NCOA3 EP300	1.98e-04	21	20	2	GO:0042975
GeneOntologyMolecularFunction	beta-catenin binding	BCL9L EP300 BCL9	2.24e-04	120	20	3	GO:0008013
GeneOntologyMolecularFunction	histone H4 acetyltransferase activity	EP300 KAT6A	2.38e-04	23	20	2	GO:0010485
GeneOntologyMolecularFunction	nuclear androgen receptor binding	NCOA3 EP300	4.94e-04	33	20	2	GO:0050681
GeneOntologyMolecularFunction	transcription factor binding	FOXA2 NCOA1 NCOA3 EP300 KAT6A	7.28e-04	753	20	5	GO:0008134
GeneOntologyMolecularFunction	nuclear receptor binding	NCOA1 NCOA3 EP300	8.19e-04	187	20	3	GO:0016922
GeneOntologyMolecularFunction	acyltransferase activity	KAT6B NCOA1 NCOA3 EP300 KAT6A	8.29e-04	775	20	5	GO:0016746
GeneOntologyMolecularFunction	nuclear estrogen receptor binding	NCOA1 NCOA3	1.27e-03	53	20	2	GO:0030331
GeneOntologyMolecularFunction	pre-mRNA binding	EP300 CELF4	1.85e-03	64	20	2	GO:0036002
GeneOntologyMolecularFunction	DNA-binding transcription activator activity, RNA polymerase II-specific	FOXA2 NCOA3 CREB5 ZIC2	2.07e-03	560	20	4	GO:0001228
GeneOntologyMolecularFunction	DNA-binding transcription activator activity	FOXA2 NCOA3 CREB5 ZIC2	2.16e-03	566	20	4	GO:0001216
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	NCOA1 NCOA3 EP300 KAT6A	2.39e-03	582	20	4	GO:0140297
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	FOXA2 NCOA1 NCOA3 EP300 CREB5 ZIC2	2.39e-03	1459	20	6	GO:0000977
GeneOntologyMolecularFunction	SMAD binding	FOXA2 EP300	3.31e-03	86	20	2	GO:0046332
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	NCOA1 NCOA3 EP300	7.92e-03	417	20	3	GO:0061629
GeneOntologyMolecularFunction	chromatin DNA binding	EP300 ZIC2	1.20e-02	167	20	2	GO:0031490
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	FOXA2 KAT6B SS18 NCOA1 BCL9L NCOA3 EP300 CREB5 ZIC2 BCL9	1.85e-07	1390	20	10	GO:0045944
GeneOntologyBiologicalProcess	stem cell population maintenance	SS18 BCL9L NCOA3 KAT6A BCL9	2.59e-06	237	20	5	GO:0019827
GeneOntologyBiologicalProcess	maintenance of cell number	SS18 BCL9L NCOA3 KAT6A BCL9	2.86e-06	242	20	5	GO:0098727
GeneOntologyBiologicalProcess	chromatin organization	FOXA2 KAT6B SS18 NCOA1 NCOA3 EP300 KAT6A	1.34e-05	896	20	7	GO:0006325
GeneOntologyBiologicalProcess	carbon catabolite activation of transcription from RNA polymerase II promoter	FOXA2 NCOA1	2.49e-05	8	20	2	GO:0000436
GeneOntologyBiologicalProcess	protein-DNA complex organization	FOXA2 KAT6B SS18 NCOA1 NCOA3 EP300 KAT6A	2.72e-05	999	20	7	GO:0071824
GeneOntologyBiologicalProcess	carbon catabolite regulation of transcription from RNA polymerase II promoter	FOXA2 NCOA1	3.20e-05	9	20	2	GO:0000429
GeneOntologyBiologicalProcess	carbon catabolite activation of transcription	FOXA2 NCOA1	3.20e-05	9	20	2	GO:0045991
GeneOntologyBiologicalProcess	carbon catabolite regulation of transcription	FOXA2 NCOA1	4.00e-05	10	20	2	GO:0045990
GeneOntologyBiologicalProcess	chromatin remodeling	KAT6B SS18 NCOA1 NCOA3 EP300 KAT6A	5.30e-05	741	20	6	GO:0006338
GeneOntologyBiologicalProcess	somatic stem cell population maintenance	BCL9L KAT6A BCL9	1.49e-04	108	20	3	GO:0035019
GeneOntologyBiologicalProcess	chordate embryonic development	FOXA2 NCOA1 NCOA3 EP300 CELF4 ZIC2	1.61e-04	906	20	6	GO:0043009
GeneOntologyBiologicalProcess	embryo development ending in birth or egg hatching	FOXA2 NCOA1 NCOA3 EP300 CELF4 ZIC2	1.85e-04	929	20	6	GO:0009792
GeneOntologyBiologicalProcess	segmentation	FOXA2 EP300 ZIC2	2.19e-04	123	20	3	GO:0035282
GeneOntologyBiologicalProcess	embryo development	FOXA2 NCOA1 NCOA3 EP300 CELF4 KAT6A ZIC2	2.71e-04	1437	20	7	GO:0009790
GeneOntologyBiologicalProcess	connective tissue development	FOXA2 NCOA1 EP300 CREB5	2.95e-04	343	20	4	GO:0061448
GeneOntologyBiologicalProcess	labyrinthine layer morphogenesis	NCOA1 NCOA3	3.33e-04	28	20	2	GO:0060713
GeneOntologyBiologicalProcess	embryonic placenta morphogenesis	NCOA1 NCOA3	4.63e-04	33	20	2	GO:0060669
GeneOntologyBiologicalProcess	enzyme-linked receptor protein signaling pathway	SLC31A1 SS18 BCL9L EP300 ZIC2 BCL9	6.88e-04	1186	20	6	GO:0007167
GeneOntologyBiologicalProcess	face morphogenesis	EP300 KAT6A	7.16e-04	41	20	2	GO:0060325
GeneOntologyBiologicalProcess	transforming growth factor beta receptor superfamily signaling pathway	BCL9L EP300 ZIC2 BCL9	7.87e-04	445	20	4	GO:0141091
GeneOntologyBiologicalProcess	regulation of transforming growth factor beta receptor signaling pathway	BCL9L EP300 BCL9	8.05e-04	192	20	3	GO:0017015
GeneOntologyBiologicalProcess	regulation of DNA-binding transcription factor activity	FOXA2 EP300 KAT6A ZIC2	8.14e-04	449	20	4	GO:0051090
GeneOntologyBiologicalProcess	regulation of cellular response to transforming growth factor beta stimulus	BCL9L EP300 BCL9	8.42e-04	195	20	3	GO:1903844
GeneOntologyBiologicalProcess	nuclear receptor-mediated signaling pathway	NCOA1 NCOA3 EP300	9.33e-04	202	20	3	GO:0141193
GeneOntologyBiologicalProcess	head morphogenesis	EP300 KAT6A	9.81e-04	48	20	2	GO:0060323
GeneOntologyBiologicalProcess	cell surface receptor protein serine/threonine kinase signaling pathway	BCL9L EP300 ZIC2 BCL9	1.06e-03	482	20	4	GO:0007178
GeneOntologyBiologicalProcess	positive regulation of stem cell population maintenance	SS18 NCOA3	1.11e-03	51	20	2	GO:1902459
GeneOntologyBiologicalProcess	skeletal muscle tissue development	BCL9L EP300 BCL9	1.24e-03	223	20	3	GO:0007519
GeneOntologyBiologicalProcess	cellular response to nutrient	FOXA2 NCOA1	1.29e-03	55	20	2	GO:0031670
GeneOntologyBiologicalProcess	skeletal muscle organ development	BCL9L EP300 BCL9	1.53e-03	240	20	3	GO:0060538
GeneOntologyBiologicalProcess	head development	FOXA2 NCOA1 EP300 KAT6A ZIC2	1.54e-03	919	20	5	GO:0060322
GeneOntologyBiologicalProcess	hormone-mediated signaling pathway	NCOA1 NCOA3 EP300	1.61e-03	244	20	3	GO:0009755
GeneOntologyBiologicalProcess	tube development	FOXA2 SLC31A1 NCOA3 EP300 KAT6A ZIC2	1.65e-03	1402	20	6	GO:0035295
GeneOntologyBiologicalProcess	face development	EP300 KAT6A	1.68e-03	63	20	2	GO:0060324
GeneOntologyBiologicalProcess	protein-DNA complex assembly	KAT6B EP300 KAT6A	1.70e-03	249	20	3	GO:0065004
GeneOntologyBiologicalProcess	labyrinthine layer development	NCOA1 NCOA3	1.74e-03	64	20	2	GO:0060711
GeneOntologyBiologicalProcess	body morphogenesis	EP300 KAT6A	1.74e-03	64	20	2	GO:0010171
GeneOntologyBiologicalProcess	protein acetylation	EP300 KAT6A	1.96e-03	68	20	2	GO:0006473
GeneOntologyBiologicalProcess	cellular response to nutrient levels	FOXA2 NCOA1 EP300	1.97e-03	262	20	3	GO:0031669
GeneOntologyBiologicalProcess	negative regulation of carbohydrate metabolic process	FOXA2 EP300	2.19e-03	72	20	2	GO:0045912
GeneOntologyBiologicalProcess	transforming growth factor beta receptor signaling pathway	BCL9L EP300 BCL9	2.28e-03	276	20	3	GO:0007179
GeneOntologyBiologicalProcess	in utero embryonic development	FOXA2 NCOA1 NCOA3 CELF4	2.31e-03	596	20	4	GO:0001701
GeneOntologyBiologicalProcess	somitogenesis	FOXA2 EP300	2.44e-03	76	20	2	GO:0001756
GeneOntologyBiologicalProcess	regulation of stem cell population maintenance	SS18 NCOA3	2.57e-03	78	20	2	GO:2000036
GeneOntologyBiologicalProcess	adipose tissue development	NCOA1 CREB5	2.63e-03	79	20	2	GO:0060612
GeneOntologyBiologicalProcess	mesenchymal cell differentiation	FOXA2 BCL9L ZIC2	2.78e-03	296	20	3	GO:0048762
GeneOntologyCellularComponent	transcription regulator complex	FOXA2 NCOA1 BCL9L NCOA3 EP300 BCL9	1.44e-05	596	20	6	GO:0005667
GeneOntologyCellularComponent	MOZ/MORF histone acetyltransferase complex	KAT6B KAT6A	1.82e-05	7	20	2	GO:0070776
GeneOntologyCellularComponent	H3 histone acetyltransferase complex	KAT6B KAT6A	2.43e-05	8	20	2	GO:0070775
GeneOntologyCellularComponent	chromatin	FOXA2 KAT6B SS18 NCOA1 NCOA3 EP300 CREB5 KAT6A	3.61e-05	1480	20	8	GO:0000785
GeneOntologyCellularComponent	beta-catenin-TCF complex	BCL9L BCL9	6.74e-05	13	20	2	GO:1990907
GeneOntologyCellularComponent	histone acetyltransferase complex	KAT6B EP300 KAT6A	9.50e-05	94	20	3	GO:0000123
GeneOntologyCellularComponent	RNA polymerase II transcription regulator complex	NCOA1 BCL9L NCOA3 BCL9	1.15e-04	272	20	4	GO:0090575
GeneOntologyCellularComponent	protein acetyltransferase complex	KAT6B EP300 KAT6A	1.28e-04	104	20	3	GO:0031248
GeneOntologyCellularComponent	acetyltransferase complex	KAT6B EP300 KAT6A	1.47e-04	109	20	3	GO:1902493
GeneOntologyCellularComponent	nuclear protein-containing complex	SS18 NCOA1 BCL9L NCOA3 PRPF40A BCL9	1.40e-03	1377	20	6	GO:0140513
HumanPheno	Laryngomalacia	KAT6B EP300 KAT6A	8.35e-05	84	6	3	HP:0001601
HumanPheno	Abnormal nasolacrimal system morphology	KAT6B EP300 KAT6A	9.28e-05	87	6	3	HP:0000614
HumanPheno	Cleft palate	FOXA2 KAT6B EP300 KAT6A ZIC2	1.70e-04	643	6	5	HP:0000175
HumanPheno	Abnormal hard palate morphology	FOXA2 KAT6B EP300 KAT6A ZIC2	1.75e-04	647	6	5	HP:0100737
HumanPheno	Abnormality of the incisor	EP300 KAT6A ZIC2	1.77e-04	108	6	3	HP:0000676
HumanPheno	Craniofacial cleft	FOXA2 KAT6B EP300 KAT6A ZIC2	2.47e-04	694	6	5	HP:5201015
HumanPheno	Orofacial cleft	FOXA2 KAT6B EP300 KAT6A ZIC2	2.47e-04	694	6	5	HP:0000202
HumanPheno	Abnormal lateral ventricle morphology	KAT6B EP300 ZIC2	3.00e-04	129	6	3	HP:0030047
HumanPheno	Abnormal male external genitalia morphology	FOXA2 KAT6B SLC31A1 EP300 KAT6A ZIC2	3.13e-04	1329	6	6	HP:0000032
HumanPheno	Agenesis of corpus callosum	FOXA2 KAT6B EP300 ZIC2	3.46e-04	365	6	4	HP:0001274
HumanPheno	Abnormal external genitalia	FOXA2 KAT6B SLC31A1 EP300 KAT6A ZIC2	3.79e-04	1372	6	6	HP:0000811
HumanPheno	Dysplastic corpus callosum	FOXA2 KAT6B EP300 ZIC2	4.71e-04	395	6	4	HP:0006989
HumanPheno	Abnormality of the male genitalia	FOXA2 KAT6B SLC31A1 EP300 KAT6A ZIC2	5.00e-04	1437	6	6	HP:0010461
HumanPheno	Abnormality of tear glands or tear production	KAT6B EP300 KAT6A	5.27e-04	156	6	3	HP:0000521
HumanPheno	Intestinal malrotation	KAT6B EP300 KAT6A	5.37e-04	157	6	3	HP:0002566
HumanPheno	Nasolacrimal duct obstruction	EP300 KAT6A	7.16e-04	36	6	2	HP:0000579
HumanPheno	Abnormal pattern of respiration	KAT6B SLC31A1 EP300 KAT6A ZIC2	7.50e-04	872	6	5	HP:0002793
HumanPheno	Cerebral visual impairment	SLC31A1 KAT6A ZIC2	7.89e-04	179	6	3	HP:0100704
HumanPheno	Short hallux	EP300 KAT6A	7.98e-04	38	6	2	HP:0010109
HumanPheno	Abnormality of the helix	KAT6B EP300 KAT6A	8.42e-04	183	6	3	HP:0000380
HumanPheno	Abnormality of upper lip vermillion	KAT6B EP300 KAT6A ZIC2	8.78e-04	464	6	4	HP:0011339
HumanPheno	Abnormal external nose morphology	FOXA2 KAT6B EP300 KAT6A ZIC2	9.51e-04	916	6	5	HP:0010938
HumanPheno	Aplasia/hypoplasia involving bones of the lower limbs	KAT6B SLC31A1 EP300 KAT6A	9.54e-04	474	6	4	HP:0006493
HumanPheno	Temperature instability	SLC31A1 ZIC2	1.02e-03	43	6	2	HP:0005968
HumanPheno	Abnormal antihelix morphology	KAT6B KAT6A	1.02e-03	43	6	2	HP:0009738
HumanPheno	Aplasia/Hypoplasia of the hallux	EP300 KAT6A	1.02e-03	43	6	2	HP:0008362
HumanPheno	Abnormal larynx morphology	KAT6B EP300 KAT6A	1.11e-03	201	6	3	HP:0025423
HumanPheno	Abnormal helix morphology	KAT6B EP300 KAT6A	1.30e-03	212	6	3	HP:0011039
HumanPheno	Abnormal hallux morphology	KAT6B EP300 KAT6A	1.30e-03	212	6	3	HP:0001844
HumanPheno	Abnormal upper lip morphology	FOXA2 KAT6B EP300 KAT6A ZIC2	1.32e-03	980	6	5	HP:0000177
HumanPheno	Gastroesophageal reflux	KAT6B EP300 KAT6A ZIC2	1.33e-03	517	6	4	HP:0002020
HumanPheno	Cutaneous syndactyly of toes	EP300 KAT6A	1.38e-03	50	6	2	HP:0010621
HumanPheno	Abnormal lacrimal duct morphology	EP300 KAT6A	1.38e-03	50	6	2	HP:0011481
HumanPheno	Hypoplasia of the toes	EP300 KAT6A	1.38e-03	50	6	2	HP:0004701
HumanPheno	Congenital malformation of the great arteries	KAT6B EP300 KAT6A ZIC2	1.45e-03	529	6	4	HP:0011603
HumanPheno	Aplasia/Hypoplasia of the earlobes	EP300 KAT6A	1.55e-03	53	6	2	HP:0009906
HumanPheno	Narrow nasal bridge	EP300 ZIC2	1.55e-03	53	6	2	HP:0000446
HumanPheno	Respiratory distress	SLC31A1 EP300 KAT6A	1.56e-03	226	6	3	HP:0002098
HumanPheno	Bilateral cryptorchidism	EP300 KAT6A	1.61e-03	54	6	2	HP:0008689
HumanPheno	Abnormal posterior pituitary morphogenesis	FOXA2 ZIC2	1.67e-03	55	6	2	HP:0011751
HumanPheno	Median cleft palate	FOXA2 ZIC2	1.73e-03	56	6	2	HP:0009099
HumanPheno	Median cleft upper lip	FOXA2 ZIC2	1.73e-03	56	6	2	HP:0000161
HumanPheno	Median cleft lip and palate	FOXA2 ZIC2	1.73e-03	56	6	2	HP:0008501
HumanPheno	Low hanging columella	EP300 KAT6A	1.73e-03	56	6	2	HP:0009765
HumanPheno	Abnormal incisor morphology	EP300 KAT6A	2.12e-03	62	6	2	HP:0011063
HumanPheno	Abnormal heart valve morphology	KAT6B SLC31A1 EP300 KAT6A	2.18e-03	588	6	4	HP:0001654
HumanPheno	Abnormal number of incisors	KAT6A ZIC2	2.19e-03	63	6	2	HP:0011064
HumanPheno	Hypoplastic ilia	KAT6B EP300	2.19e-03	63	6	2	HP:0000946
HumanPheno	Abnormal nasal dorsum morphology	FOXA2 EP300 ZIC2	2.40e-03	262	6	3	HP:0011119
HumanPheno	Hydronephrosis	KAT6B EP300 KAT6A	2.45e-03	264	6	3	HP:0000126
MousePheno	kinked neural tube	FOXA2 SS18 EP300	5.95e-05	57	19	3	MP:0003400
MousePheno	abnormal prenatal growth/weight/body size	FOXA2 SLC31A1 SS18 BCL9L NCOA3 EP300 CELF4 KAT6A BCL9	6.01e-05	1493	19	9	MP:0004196
Domain	Nuc_rcpt_coact	NCOA1 NCOA3 EP300	2.10e-08	6	20	3	IPR009110
Domain	BCL9_beta-catenin-bd_dom	BCL9L BCL9	1.09e-06	2	20	2	IPR024670
Domain	BCL9	BCL9L BCL9	1.09e-06	2	20	2	PF11502
Domain	Bcl-9	BCL9L BCL9	1.09e-06	2	20	2	IPR015668
Domain	DUF1518	NCOA1 NCOA3	3.27e-06	3	20	2	SM01151
Domain	Nuc_rcpt_coact_Ncoa-typ	NCOA1 NCOA3	3.27e-06	3	20	2	IPR014920
Domain	SRC-1	NCOA1 NCOA3	3.27e-06	3	20	2	IPR014935
Domain	SRC-1	NCOA1 NCOA3	3.27e-06	3	20	2	PF08832
Domain	DUF1518	NCOA1 NCOA3	3.27e-06	3	20	2	PF07469
Domain	-	NCOA1 NCOA3	3.27e-06	3	20	2	4.10.630.10
Domain	DUF1518	NCOA1 NCOA3	3.27e-06	3	20	2	IPR010011
Domain	Nuc_rec_co-act	NCOA1 NCOA3	3.27e-06	3	20	2	PF08815
Domain	Src1_rcpt_coact	NCOA1 NCOA3	3.27e-06	3	20	2	IPR008955
Domain	Nuclear_rcpt_coactivator	NCOA1 NCOA3	3.27e-06	3	20	2	IPR017426
Domain	MOZ_SAS	KAT6B KAT6A	1.09e-05	5	20	2	PF01853
Domain	HAT_MYST-type	KAT6B KAT6A	1.09e-05	5	20	2	IPR002717
Domain	MYST_HAT	KAT6B KAT6A	1.09e-05	5	20	2	PS51726
Domain	H15	KAT6B KAT6A	8.44e-05	13	20	2	PS51504
Domain	H15	KAT6B KAT6A	8.44e-05	13	20	2	SM00526
Domain	Histone_H1/H5_H15	KAT6B KAT6A	9.84e-05	14	20	2	IPR005818
Domain	PAS	NCOA1 NCOA3	3.22e-04	25	20	2	PF00989
Domain	PAS_fold	NCOA1 NCOA3	3.22e-04	25	20	2	IPR013767
Domain	PAS	NCOA1 NCOA3	5.30e-04	32	20	2	SM00091
Domain	PAS	NCOA1 NCOA3	5.99e-04	34	20	2	IPR000014
Domain	PAS	NCOA1 NCOA3	5.99e-04	34	20	2	PS50112
Domain	-	KAT6B KAT6A	8.29e-04	40	20	2	3.40.630.30
Domain	Acyl_CoA_acyltransferase	KAT6B KAT6A	1.05e-03	45	20	2	IPR016181
Domain	-	FOXA2 KAT6B KAT6A	1.54e-03	218	20	3	1.10.10.10
Domain	WHTH_DNA-bd_dom	FOXA2 KAT6B KAT6A	2.08e-03	242	20	3	IPR011991
Domain	PHD	KAT6B KAT6A	2.88e-03	75	20	2	PF00628
Domain	Znf_PHD-finger	KAT6B KAT6A	3.19e-03	79	20	2	IPR019787
Domain	PHD	KAT6B KAT6A	4.03e-03	89	20	2	SM00249
Domain	Znf_PHD	KAT6B KAT6A	4.21e-03	91	20	2	IPR001965
Domain	ZF_PHD_2	KAT6B KAT6A	4.58e-03	95	20	2	PS50016
Domain	ZF_PHD_1	KAT6B KAT6A	4.68e-03	96	20	2	PS01359
Domain	-	NCOA1 NCOA3	5.99e-03	109	20	2	4.10.280.10
Domain	HLH	NCOA1 NCOA3	6.20e-03	111	20	2	PF00010
Domain	HLH	NCOA1 NCOA3	6.75e-03	116	20	2	SM00353
Domain	BHLH	NCOA1 NCOA3	6.87e-03	117	20	2	PS50888
Domain	bHLH_dom	NCOA1 NCOA3	6.98e-03	118	20	2	IPR011598
Domain	Znf_FYVE_PHD	KAT6B KAT6A	1.07e-02	147	20	2	IPR011011
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	BCL9L EP300 BCL9	4.46e-06	26	18	3	MM14793
Pathway	PID_RETINOIC_ACID_PATHWAY	NCOA1 NCOA3 EP300	6.95e-06	30	18	3	M207
Pathway	KEGG_MEDICUS_VARIANT_ESR1_POSITIVE_TO_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	NCOA1 NCOA3	1.54e-05	5	18	2	M48983
Pathway	PID_HNF3A_PATHWAY	FOXA2 NCOA3 EP300	2.24e-05	44	18	3	M285
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	KAT6B NCOA1 KAT6A	2.56e-05	46	18	3	MM14935
Pathway	REACTOME_HATS_ACETYLATE_HISTONES	KAT6B NCOA1 EP300 KAT6A	2.71e-05	142	18	4	M27233
Pathway	BIOCARTA_PPARG_PATHWAY	NCOA1 EP300	4.29e-05	8	18	2	M22058
Pathway	PID_ERA_GENOMIC_PATHWAY	NCOA1 NCOA3 EP300	6.94e-05	64	18	3	M200
Pathway	KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	NCOA1 NCOA3	8.41e-05	11	18	2	M47503
Pathway	REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING	NCOA1 EP300	1.19e-04	13	18	2	MM15622
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	NCOA1 NCOA3 EP300	1.56e-04	84	18	3	M1008
Pathway	PID_ERB_GENOMIC_PATHWAY	NCOA1 NCOA3	1.60e-04	15	18	2	M119
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	BCL9L EP300 BCL9	1.98e-04	91	18	3	M27101
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA1 NCOA3 EP300	1.98e-04	91	18	3	M39700
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	NCOA1 EP300	2.33e-04	18	18	2	M26942
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	KAT6B NCOA1 EP300 KAT6A	3.35e-04	272	18	4	M29619
Pathway	REACTOME_ADIPOGENESIS	NCOA1 NCOA3 EP300	3.46e-04	110	18	3	M48259
Pathway	BIOCARTA_VDR_PATHWAY	NCOA3 EP300	3.50e-04	22	18	2	MM1370
Pathway	BIOCARTA_VDR_PATHWAY	NCOA1 EP300	4.18e-04	24	18	2	M13404
Pathway	REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA	NCOA1 NCOA3 EP300	4.26e-04	118	18	3	M27316
Pathway	REACTOME_GASTRULATION	FOXA2 EP300 ZIC2	5.52e-04	129	18	3	M46433
Pathway	WP_NUCLEAR_RECEPTORS_METAPATHWAY	NCOA1 NCOA3 EP300 ZIC2	5.77e-04	314	18	4	M39428
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	EP300 KAT6A	6.13e-04	29	18	2	MM15340
Pathway	REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	EP300 KAT6A	6.56e-04	30	18	2	M27637
Pathway	WP_PREGNANE_X_RECEPTOR_PATHWAY	NCOA1 NCOA3	7.47e-04	32	18	2	M39567
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	NCOA1 NCOA3 EP300	8.40e-04	149	18	3	M27888
Pathway	REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT	BCL9L EP300 BCL9	9.96e-04	158	18	3	MM14791
Pathway	REACTOME_NR1H3_NR1H2_REGULATE_GENE_EXPRESSION_LINKED_TO_CHOLESTEROL_TRANSPORT_AND_EFFLUX	NCOA1 EP300	9.99e-04	37	18	2	M29790
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	NCOA1 EP300	1.17e-03	40	18	2	MM15000
Pathway	REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	FOXA2 EP300	1.29e-03	42	18	2	M17541
Pathway	REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX	BCL9L BCL9	1.29e-03	42	18	2	M27272
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	KAT6B NCOA1 KAT6A	1.34e-03	175	18	3	MM14941
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	NCOA1 EP300	1.41e-03	44	18	2	M27295
Pathway	WP_ARYL_HYDROCARBON_RECEPTOR_PATHWAY_WP2873	NCOA1 EP300	1.48e-03	45	18	2	M39615
Pathway	REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING	NCOA1 EP300	1.61e-03	47	18	2	M29777
Pathway	WP_ENERGY_METABOLISM	NCOA1 EP300	1.68e-03	48	18	2	M39590
Pathway	PID_HES_HEY_PATHWAY	NCOA1 EP300	1.68e-03	48	18	2	M288
Pathway	REACTOME_HEME_SIGNALING	NCOA1 EP300	1.75e-03	49	18	2	M41832
Pathway	BIOCARTA_PPARA_PATHWAY	NCOA1 EP300	1.97e-03	52	18	2	M2404
Pathway	PID_AR_TF_PATHWAY	NCOA1 EP300	2.04e-03	53	18	2	M151
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	NCOA1 NCOA3 EP300	2.57e-03	220	18	3	M27794
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	NCOA1 EP300	2.87e-03	63	18	2	MM15613
Pathway	REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT	BCL9L EP300 BCL9	3.03e-03	233	18	3	M27099
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	EP300 KAT6A	3.05e-03	65	18	2	M39682
Pathway	PID_HIF1_TFPATHWAY	NCOA1 EP300	3.15e-03	66	18	2	M255
Pathway	REACTOME_SIGNALING_BY_WNT	BCL9L EP300 BCL9	3.25e-03	239	18	3	MM14756
Pathway	REACTOME_CIRCADIAN_CLOCK	NCOA1 EP300	3.53e-03	70	18	2	M938
Pathway	PID_BETA_CATENIN_NUC_PATHWAY	EP300 BCL9	4.59e-03	80	18	2	M223
Pathway	PID_REG_GR_PATHWAY	NCOA1 EP300	4.81e-03	82	18	2	M115
Pathway	PID_SMAD2_3NUCLEAR_PATHWAY	NCOA1 EP300	4.81e-03	82	18	2	M2
Pathway	KEGG_PROSTATE_CANCER	EP300 CREB5	5.65e-03	89	18	2	M13191
Pathway	WNT_SIGNALING	EP300 BCL9	5.65e-03	89	18	2	M5493
Pathway	REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS	NCOA1 NCOA3 EP300	5.92e-03	296	18	3	M27869
Pathway	WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY	NCOA1 EP300 ZIC2	6.20e-03	301	18	3	MM15983
Pubmed	New nomenclature for chromatin-modifying enzymes.	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.50e-10	57	20	5	18022353
Pubmed	Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replication.	KAT6B EP300 KAT6A	1.62e-09	5	20	3	17182677
Pubmed	SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4.	NCOA1 NCOA3 EP300	1.62e-09	5	20	3	9812974
Pubmed	Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.	NCOA1 NCOA3 EP300	1.62e-09	5	20	3	12714702
Pubmed	Temporal/spatial expression of nuclear receptor coactivators in the mouse lung.	NCOA1 NCOA3 EP300	3.25e-09	6	20	3	11076796
Pubmed	Roles of coactivators in hypoxic induction of the erythropoietin gene.	NCOA1 NCOA3 EP300	3.25e-09	6	20	3	20368990
Pubmed	Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly.	NCOA1 NCOA3 EP300	3.25e-09	6	20	3	16923966
Pubmed	The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine.	NCOA1 NCOA3 EP300	5.68e-09	7	20	3	12709428
Pubmed	The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment.	NCOA1 NCOA3 EP300	9.09e-09	8	20	3	12082103
Pubmed	Aberrant association of promyelocytic leukemia protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene expression.	NCOA1 NCOA3 EP300	9.09e-09	8	20	3	17475621
Pubmed	Acetylation of HIV-1 integrase by p300 regulates viral integration.	KAT6B EP300 KAT6A	2.68e-08	11	20	3	16096645
Pubmed	Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.	NCOA1 NCOA3 EP300	5.90e-08	14	20	3	11500849
Pubmed	Deterministic and stochastic allele specific gene expression in single mouse blastomeres.	FOXA2 KAT6B SLC31A1 NCOA1 NCOA3 KAT6A	1.06e-07	424	20	6	21731673
Pubmed	Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.	BCL9L NCOA3 PRPF40A EP300 CREB5 BCL9	1.08e-07	425	20	6	24999758
Pubmed	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.	NCOA1 NCOA3 EP300	1.10e-07	17	20	3	19183483
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	FOXA2 BCL9L NCOA3 PRPF40A EP300 BCL9	1.65e-07	457	20	6	32344865
Pubmed	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.	NCOA1 NCOA3 EP300	1.84e-07	20	20	3	11877444
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA1 NCOA3 EP300	2.15e-07	21	20	3	19596656
Pubmed	Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells.	FOXA2 NCOA1 NCOA3	2.86e-07	23	20	3	19737349
Pubmed	p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion.	SS18 EP300	3.14e-07	2	20	2	11030627
Pubmed	Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance.	NCOA1 NCOA3	3.14e-07	2	20	2	16459312
Pubmed	MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).	EP300 KAT6A	3.14e-07	2	20	2	10824998
Pubmed	The coactivator SRC-1 is an essential coordinator of hepatic glucose production.	NCOA1 NCOA3	3.14e-07	2	20	2	21109193
Pubmed	ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B.	KAT6B KAT6A	3.14e-07	2	20	2	39505971
Pubmed	Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor.	NCOA1 NCOA3	3.14e-07	2	20	2	16141356
Pubmed	Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.	BCL9L BCL9	3.14e-07	2	20	2	20682801
Pubmed	Immunohistochemical localization of steroid receptor coactivators in chondrosarcoma: an in vivo tissue microarray study.	NCOA1 NCOA3	3.14e-07	2	20	2	24875297
Pubmed	Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.	BCL9L BCL9	3.14e-07	2	20	2	38811552
Pubmed	NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia.	NCOA3 KAT6A	3.14e-07	2	20	2	17805331
Pubmed	BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.	BCL9L BCL9	3.14e-07	2	20	2	33767438
Pubmed	Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease.	KAT6B KAT6A	3.14e-07	2	20	2	27185879
Pubmed	Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.	BCL9L BCL9	3.14e-07	2	20	2	15371335
Pubmed	The double PHD finger domain of MOZ/MYST3 induces α-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification.	KAT6B KAT6A	3.14e-07	2	20	2	24150941
Pubmed	Role of accessory factors and steroid receptor coactivator 1 in the regulation of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids.	FOXA2 NCOA1	3.14e-07	2	20	2	11069927
Pubmed	Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action.	NCOA1 NCOA3 EP300	5.28e-07	28	20	3	24880616
Pubmed	MORF and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain.	KAT6B KAT6A	9.42e-07	3	20	2	36754959
Pubmed	Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.	NCOA1 EP300	9.42e-07	3	20	2	11773079
Pubmed	The transcriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles.	NCOA1 NCOA3	9.42e-07	3	20	2	21035760
Pubmed	Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators.	NCOA3 EP300	9.42e-07	3	20	2	11823864
Pubmed	Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.	NCOA1 NCOA3	9.42e-07	3	20	2	18845648
Pubmed	The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.	NCOA1 NCOA3	9.42e-07	3	20	2	12138202
Pubmed	Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.	NCOA1 NCOA3	9.42e-07	3	20	2	21059860
Pubmed	AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor.	NCOA3 EP300	9.42e-07	3	20	2	10866661
Pubmed	The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6.	NCOA3 EP300	9.42e-07	3	20	2	15145939
Pubmed	The nuclear hormone receptor coactivator SRC-1 is a specific target of p300.	NCOA1 EP300	9.42e-07	3	20	2	8855229
Pubmed	Dynamics changes in the transcription factors during early human embryonic development.	FOXA2 EP300	9.42e-07	3	20	2	30246428
Pubmed	Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.	NCOA1 NCOA3	9.42e-07	3	20	2	9832502
Pubmed	Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.	KAT6B KAT6A	9.42e-07	3	20	2	23063713
Pubmed	The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.	BCL9L BCL9	9.42e-07	3	20	2	34545187
Pubmed	Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.	NCOA1 NCOA3	9.42e-07	3	20	2	16675958
Pubmed	Differential regulation of β-catenin-mediated transcription via N- and C-terminal co-factors governs identity of murine intestinal epithelial stem cells.	BCL9L BCL9	9.42e-07	3	20	2	33649334
Pubmed	Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene.	NCOA1 NCOA3	9.42e-07	3	20	2	9506940
Pubmed	Structure and chromosomal locations of mouse steroid receptor coactivator gene family.	NCOA1 NCOA3	9.42e-07	3	20	2	10501088
Pubmed	Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators.	NCOA1 NCOA3	9.42e-07	3	20	2	22142990
Pubmed	Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers.	NCOA1 NCOA3	9.42e-07	3	20	2	28390937
Pubmed	The transcriptional coactivators p/CIP and SRC-1 control insulin resistance through IRS1 in obesity models.	NCOA1 NCOA3	9.42e-07	3	20	2	22859932
Pubmed	The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis.	NCOA1 NCOA3	9.42e-07	3	20	2	19383905
Pubmed	p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha.	NCOA1 EP300	9.42e-07	3	20	2	9407140
Pubmed	Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor.	BCL9L BCL9	9.42e-07	3	20	2	20637214
Pubmed	A mutant form of ERα associated with estrogen insensitivity affects the coupling between ligand binding and coactivator recruitment.	NCOA1 NCOA3	9.42e-07	3	20	2	32963012
Pubmed	Mediator and p300/CBP-steroid receptor coactivator complexes have distinct roles, but function synergistically, during estrogen receptor alpha-dependent transcription with chromatin templates.	NCOA1 EP300	9.42e-07	3	20	2	12482985
Pubmed	Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences.	NCOA1 NCOA3	9.42e-07	3	20	2	23927929
Pubmed	Co-activator SRC-1 is dispensable for transcriptional control by STAT3.	NCOA1 EP300	9.42e-07	3	20	2	19203349
Pubmed	The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription.	NCOA3 EP300	9.42e-07	3	20	2	12569362
Pubmed	The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism.	NCOA1 NCOA3	9.42e-07	3	20	2	16423883
Pubmed	Interaction network of human early embryonic transcription factors.	NCOA1 BCL9L NCOA3 EP300 BCL9	1.39e-06	351	20	5	38297188
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	NCOA1 NCOA3 EP300 BCL9	1.61e-06	152	20	4	38360978
Pubmed	The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.	KAT6B SS18 EP300 KAT6A	1.83e-06	157	20	4	30186101
Pubmed	miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.	NCOA1 NCOA3	1.88e-06	4	20	2	26066330
Pubmed	CBP/p300 interact with and function as transcriptional coactivators of BRCA1.	NCOA3 EP300	1.88e-06	4	20	2	10655477
Pubmed	Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53.	NCOA1 NCOA3	1.88e-06	4	20	2	10551785
Pubmed	Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1).	NCOA3 EP300	1.88e-06	4	20	2	16227615
Pubmed	Synovial sarcoma translocation (SYT) encodes a nuclear receptor coactivator.	SS18 NCOA1	1.88e-06	4	20	2	15919756
Pubmed	Analysis of the steroid receptor coactivator 1 (SRC1)-CREB binding protein interaction interface and its importance for the function of SRC1.	NCOA1 EP300	1.88e-06	4	20	2	11113179
Pubmed	Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.	NCOA3 EP300	1.88e-06	4	20	2	33589584
Pubmed	Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes.	NCOA3 EP300	1.88e-06	4	20	2	32668201
Pubmed	Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF).	KAT6B KAT6A	1.88e-06	4	20	2	21880731
Pubmed	Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy.	NCOA1 NCOA3	1.88e-06	4	20	2	22560224
Pubmed	The interaction of ETV6 (TEL) and TIP60 requires a functional histone acetyltransferase domain in TIP60.	KAT6B KAT6A	1.88e-06	4	20	2	17980166
Pubmed	P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain.	NCOA1 NCOA3	1.88e-06	4	20	2	18267973
Pubmed	Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells.	NCOA1 NCOA3	1.88e-06	4	20	2	15331759
Pubmed	Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium.	NCOA1 EP300	1.88e-06	4	20	2	12574227
Pubmed	A simple method to screen ligands of peroxisome proliferator-activated receptor delta.	NCOA1 EP300	1.88e-06	4	20	2	16930961
Pubmed	Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.	NCOA1 EP300	1.88e-06	4	20	2	12208951
Pubmed	Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death.	NCOA1 NCOA3	1.88e-06	4	20	2	26267537
Pubmed	A transcriptional switch mediated by cofactor methylation.	NCOA3 EP300	1.88e-06	4	20	2	11701890
Pubmed	BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration.	BCL9L BCL9	1.88e-06	4	20	2	19699733
Pubmed	The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation.	NCOA1 EP300	1.88e-06	4	20	2	11463834
Pubmed	Mutation of a lysine residue in a homeodomain generates dominant negative thyroid transcription factor 1.	NCOA1 NCOA3	1.88e-06	4	20	2	15449938
Pubmed	Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.	NCOA1 NCOA3	1.88e-06	4	20	2	20003447
Pubmed	The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP.	NCOA1 EP300	1.88e-06	4	20	2	15688032
Pubmed	Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.	NCOA1 NCOA3	1.88e-06	4	20	2	19095746
Pubmed	Nuclear hormone receptor coregulator GRIP1 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD.	NCOA1 NCOA3	1.88e-06	4	20	2	15563453
Pubmed	Transcription activation by the orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI). Definition of the domain involved in the glucocorticoid response of the phosphoenolpyruvate carboxykinase gene.	NCOA1 NCOA3	3.14e-06	5	20	2	10652338
Pubmed	Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models.	BCL9L BCL9	3.14e-06	5	20	2	30760710
Pubmed	Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor.	NCOA1 NCOA3	3.14e-06	5	20	2	18798693
Pubmed	Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.	NCOA1 NCOA3	3.14e-06	5	20	2	12554772
Pubmed	Redundant enhancement of mouse constitutive androstane receptor transactivation by p160 coactivator family members.	NCOA1 NCOA3	3.14e-06	5	20	2	17950690
Pubmed	Structure of a biologically active estrogen receptor-coactivator complex on DNA.	NCOA3 EP300	3.14e-06	5	20	2	25728767
Pubmed	SIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm.	NCOA1 NCOA3	3.14e-06	5	20	2	17476305
Interaction	SP7 interactions	SS18 NCOA1 BCL9L NCOA3 PRPF40A EP300 BCL9	1.09e-08	304	20	7	int:SP7
Interaction	GSC interactions	FOXA2 BCL9L NCOA3 EP300 BCL9	1.97e-08	87	20	5	int:GSC
Interaction	FOS interactions	SS18 NCOA1 NCOA3 EP300 CREB5 BCL9	4.24e-07	312	20	6	int:FOS
Interaction	GCM1 interactions	SS18 NCOA3 EP300 BCL9	5.51e-07	68	20	4	int:GCM1
Interaction	EGR2 interactions	NCOA1 BCL9L NCOA3 EP300 BCL9	5.80e-07	171	20	5	int:EGR2
Interaction	ETV4 interactions	SS18 NCOA3 EP300 BCL9	5.85e-07	69	20	4	int:ETV4
Interaction	MYOD1 interactions	SS18 NCOA1 NCOA3 EP300 BCL9	1.08e-06	194	20	5	int:MYOD1
Interaction	EWSR1 interactions	BCL9L NCOA3 PRPF40A EP300 CREB5 CLINT1 KAT6A BCL9	1.26e-06	906	20	8	int:EWSR1
Interaction	ERG interactions	SS18 NCOA3 PRPF40A EP300 BCL9	2.15e-06	223	20	5	int:ERG
Interaction	NUP35 interactions	FOXA2 BCL9L NCOA3 PRPF40A EP300 BCL9	2.53e-06	424	20	6	int:NUP35
Interaction	CRX interactions	NCOA1 BCL9L NCOA3 EP300 BCL9	4.06e-06	254	20	5	int:CRX
Interaction	TBR1 interactions	BCL9L NCOA3 EP300 BCL9	4.24e-06	113	20	4	int:TBR1
Interaction	TBXT interactions	SS18 NCOA3 EP300 BCL9	4.70e-06	116	20	4	int:TBXT
Interaction	HNF4A interactions	FOXA2 SS18 NCOA1 NCOA3 EP300	5.98e-06	275	20	5	int:HNF4A
Interaction	PAX7 interactions	SS18 NCOA3 EP300 BCL9	6.13e-06	124	20	4	int:PAX7
Interaction	SMARCE1 interactions	SS18 NCOA1 NCOA3 PRPF40A EP300	7.36e-06	287	20	5	int:SMARCE1
Interaction	PAX9 interactions	BCL9L NCOA3 EP300 BCL9	7.39e-06	130	20	4	int:PAX9
Interaction	HEMGN interactions	DCAF15 EP300 KAT6A	1.08e-05	44	20	3	int:HEMGN
Interaction	NCOA1 interactions	FOXA2 NCOA1 NCOA3 EP300	1.17e-05	146	20	4	int:NCOA1
Interaction	RARB interactions	NCOA1 NCOA3 EP300	1.23e-05	46	20	3	int:RARB
Interaction	NR1I2 interactions	NCOA1 NCOA3 EP300	1.41e-05	48	20	3	int:NR1I2
Interaction	TLX1 interactions	NCOA3 EP300 KAT6A BCL9	2.39e-05	175	20	4	int:TLX1
Interaction	RARG interactions	NCOA1 NCOA3 EP300	2.49e-05	58	20	3	int:RARG
Interaction	NR1H3 interactions	NCOA1 NCOA3 EP300	2.49e-05	58	20	3	int:NR1H3
Interaction	SSBP4 interactions	BCL9L EP300 BCL9	2.62e-05	59	20	3	int:SSBP4
Interaction	TLE3 interactions	NCOA1 BCL9L NCOA3 EP300 BCL9	2.71e-05	376	20	5	int:TLE3
Interaction	ALG13 interactions	NCOA3 PRPF40A EP300 BCL9	2.84e-05	183	20	4	int:ALG13
Interaction	ETS2 interactions	NCOA1 NCOA3 EP300	2.90e-05	61	20	3	int:ETS2
Interaction	SMARCC1 interactions	SS18 NCOA1 NCOA3 PRPF40A EP300	3.00e-05	384	20	5	int:SMARCC1
Interaction	AR interactions	NCOA1 BCL9L NCOA3 PRPF40A MLF2 EP300 BCL9	3.02e-05	992	20	7	int:AR
Interaction	GATA3 interactions	NCOA3 PRPF40A EP300 BCL9	3.10e-05	187	20	4	int:GATA3
Interaction	SOX2 interactions	KAT6B SS18 BCL9L NCOA3 MLF2 EP300 CLINT1 BCL9	3.52e-05	1422	20	8	int:SOX2
Interaction	KLF5 interactions	SS18 NCOA3 EP300 BCL9	3.65e-05	195	20	4	int:KLF5
Interaction	GATA2 interactions	SS18 NCOA3 EP300 BCL9	3.95e-05	199	20	4	int:GATA2
Interaction	ASCC1 interactions	NCOA1 EP300 KAT6A	4.58e-05	71	20	3	int:ASCC1
Interaction	ING4 interactions	KAT6B EP300 KAT6A	6.06e-05	78	20	3	int:ING4
Interaction	HNF1A interactions	NCOA1 NCOA3 EP300	6.54e-05	80	20	3	int:HNF1A
Interaction	CDK12 interactions	DCAF15 PRPF40A EP300 KAT6A	6.70e-05	228	20	4	int:CDK12
Interaction	SOX7 interactions	NCOA1 NCOA3 EP300	7.04e-05	82	20	3	int:SOX7
Interaction	SMARCA4 interactions	SS18 NCOA1 PRPF40A EP300 KAT6A	7.23e-05	462	20	5	int:SMARCA4
Interaction	PGR interactions	NCOA1 NCOA3 EP300	7.57e-05	84	20	3	int:PGR
Interaction	JUN interactions	NCOA1 NCOA3 EP300 CREB5 CLINT1	7.84e-05	470	20	5	int:JUN
Interaction	IRF4 interactions	SS18 NCOA3 EP300	7.84e-05	85	20	3	int:IRF4
Interaction	STAT6 interactions	NCOA1 NCOA3 EP300	8.40e-05	87	20	3	int:STAT6
Interaction	EYA4 interactions	NCOA1 NCOA3 EP300 BCL9	8.58e-05	243	20	4	int:EYA4
Interaction	PPARA interactions	NCOA1 NCOA3 EP300	9.92e-05	92	20	3	int:PPARA
Interaction	FOXI1 interactions	NCOA3 EP300 BCL9	9.92e-05	92	20	3	int:FOXI1
Interaction	SOX10 interactions	NCOA3 EP300 BCL9	9.92e-05	92	20	3	int:SOX10
Interaction	HOXA5 interactions	FOXA2 PRPF40A KAT6A	1.06e-04	94	20	3	int:HOXA5
Interaction	SOX17 interactions	SS18 NCOA3 BCL9	1.09e-04	95	20	3	int:SOX17
Interaction	SOX9 interactions	NCOA3 EP300 BCL9	1.16e-04	97	20	3	int:SOX9
Interaction	AMBRA1 interactions	RAB40C PRPF40A MLF2 KAT6A	1.20e-04	265	20	4	int:AMBRA1
Interaction	POP1 interactions	PRPF40A MLF2 EP300 KAT6A	1.42e-04	277	20	4	int:POP1
Interaction	SSBP2 interactions	BCL9L EP300 BCL9	1.47e-04	105	20	3	int:SSBP2
Interaction	WDR44 interactions	SLC31A1 DCAF15 EP300	1.47e-04	105	20	3	int:WDR44
Interaction	CCND1 interactions	NCOA1 NCOA3 MLF2 EP300	1.61e-04	286	20	4	int:CCND1
Interaction	KLF15 interactions	NCOA1 NCOA3 EP300 BCL9	1.70e-04	290	20	4	int:KLF15
Interaction	TLX3 interactions	BCL9L NCOA3 EP300 BCL9	1.72e-04	291	20	4	int:TLX3
Interaction	PAX8 interactions	NCOA3 EP300 BCL9	1.73e-04	111	20	3	int:PAX8
Interaction	THRA interactions	NCOA1 NCOA3 EP300	1.73e-04	111	20	3	int:THRA
Interaction	FOXM1 interactions	SLC31A1 DCAF15 EP300	1.83e-04	113	20	3	int:FOXM1
Interaction	ING5 interactions	KAT6B EP300 KAT6A	1.87e-04	114	20	3	int:ING5
Interaction	LDB1 interactions	BCL9L EP300 BCL9	1.92e-04	115	20	3	int:LDB1
Interaction	KLF13 interactions	EP300 KAT6A	1.94e-04	21	20	2	int:KLF13
Interaction	PPARD interactions	NCOA1 NCOA3 EP300	2.02e-04	117	20	3	int:PPARD
Interaction	HNF4G interactions	NCOA1 NCOA3	2.14e-04	22	20	2	int:HNF4G
Interaction	ETS1 interactions	NCOA1 NCOA3 EP300	2.23e-04	121	20	3	int:ETS1
Interaction	RUNX2 interactions	KAT6B NCOA1 EP300	2.52e-04	126	20	3	int:RUNX2
Interaction	NR6A1 interactions	NCOA1 EP300	2.55e-04	24	20	2	int:NR6A1
Interaction	VDR interactions	NCOA1 NCOA3 EP300	2.58e-04	127	20	3	int:VDR
Interaction	EP300 interactions	SS18 NCOA1 NCOA3 PRPF40A EP300 CLINT1 KAT6A	2.68e-04	1401	20	7	int:EP300
Interaction	RABL6 interactions	DCAF15 PRPF40A EP300	2.76e-04	130	20	3	int:RABL6
Interaction	TLE6 interactions	NCOA3 EP300	2.77e-04	25	20	2	int:TLE6
Interaction	SETSIP interactions	EP300 KAT6A	2.77e-04	25	20	2	int:SETSIP
Interaction	PYGO1 interactions	BCL9L BCL9	3.48e-04	28	20	2	int:PYGO1
Interaction	SOX15 interactions	NCOA3 EP300 BCL9	3.50e-04	141	20	3	int:SOX15
Interaction	NCOA2 interactions	NCOA1 NCOA3 EP300	3.50e-04	141	20	3	int:NCOA2
Interaction	GTF2B interactions	NCOA1 NCOA3 EP300	3.50e-04	141	20	3	int:GTF2B
Interaction	SMARCC2 interactions	SS18 NCOA3 PRPF40A EP300	3.59e-04	353	20	4	int:SMARCC2
Interaction	ETV1 interactions	NCOA3 EP300	3.74e-04	29	20	2	int:ETV1
Interaction	MN1 interactions	NCOA3 EP300	3.74e-04	29	20	2	int:MN1
Interaction	MYOCD interactions	NCOA3 EP300	3.74e-04	29	20	2	int:MYOCD
Interaction	TOE1 interactions	RAB40C EP300 KAT6A	3.88e-04	146	20	3	int:TOE1
Interaction	ELF5 interactions	SS18 PRPF40A EP300	3.96e-04	147	20	3	int:ELF5
Interaction	DDA1 interactions	RAB40C DCAF15 EP300 KAT6A	4.20e-04	368	20	4	int:DDA1
Interaction	TCEAL9 interactions	DCAF15 PRPF40A	4.28e-04	31	20	2	int:TCEAL9
Interaction	SPATA1 interactions	PRPF40A EP300	4.28e-04	31	20	2	int:SPATA1
Interaction	H4C16 interactions	NCOA3 EP300 KAT6A	4.36e-04	152	20	3	int:H4C16
Interaction	NR1H4 interactions	NCOA1 EP300	4.56e-04	32	20	2	int:NR1H4
Interaction	ZRANB3 interactions	SLC31A1 DCAF15	4.85e-04	33	20	2	int:ZRANB3
Interaction	MEX3A interactions	SS18 BCL9L EP300 KAT6A	4.94e-04	384	20	4	int:MEX3A
Interaction	YLPM1 interactions	DCAF15 PRPF40A EP300	5.07e-04	160	20	3	int:YLPM1
Interaction	KLF4 interactions	NCOA3 EP300 BCL9	5.07e-04	160	20	3	int:KLF4
Interaction	KAT6B interactions	KAT6B KAT6A	5.15e-04	34	20	2	int:KAT6B
Interaction	FOXA2 interactions	FOXA2 NCOA1	5.46e-04	35	20	2	int:FOXA2
Interaction	PPIL4 interactions	PRPF40A EP300 KAT6A	5.55e-04	165	20	3	int:PPIL4
Interaction	HOXB2 interactions	NCOA1 EP300	5.78e-04	36	20	2	int:HOXB2
Interaction	RXRA interactions	NCOA1 NCOA3 EP300	5.95e-04	169	20	3	int:RXRA
Interaction	NRIP1 interactions	NCOA1 NCOA3 PRPF40A	6.05e-04	170	20	3	int:NRIP1
Interaction	GATA1 interactions	PRPF40A EP300 BCL9	6.15e-04	171	20	3	int:GATA1
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	KAT6B NCOA1 NCOA3 EP300 KAT6A	3.03e-13	17	12	5	486
GeneFamily	Zinc fingers C2HC-type\|PHD finger proteins\|Lysine acetyltransferases	KAT6B KAT6A	4.82e-05	16	12	2	66
GeneFamily	PHD finger proteins	KAT6B KAT6A	1.57e-03	90	12	2	88
GeneFamily	Basic helix-loop-helix proteins	NCOA1 NCOA3	2.33e-03	110	12	2	420
Coexpression	GSE7764_IL15_NK_CELL_24H_VS_SPLENOCYTE_DN	NCOA3 EP300 KAT6A BCL9	1.42e-05	199	20	4	M5726
Coexpression	GSE45881_CXCR6HI_VS_CXCR1LO_COLONIC_LAMINA_PROPRIA_UP	DCAF15 PRPF40A EP300 KAT6A	1.45e-05	200	20	4	M9889
Coexpression	GSE17721_PAM3CSK4_VS_GADIQUIMOD_2H_BMDC_DN	RAB40C NCOA1 DCAF15 CLINT1	1.45e-05	200	20	4	M3965
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	KAT6B NCOA1 NCOA3 CREB5 CLINT1 KAT6A	3.12e-05	856	20	6	M4500
Coexpression	GRESHOCK_CANCER_COPY_NUMBER_UP	KAT6B SS18 EP300 BCL9	9.38e-05	323	20	4	M9150
Coexpression	ZHONG_PFC_C5_BCL11B_CALB2_POS_INP	KAT6B CELF4	1.27e-04	22	20	2	M39085
Coexpression	GSE3920_UNTREATED_VS_IFNG_TREATED_FIBROBLAST_UP	FOXA2 NCOA1 DCAF15	2.63e-04	166	20	3	M6688
Coexpression	GSE6269_FLU_VS_STREP_PNEUMO_INF_PBMC_UP	NCOA3 DCAF15 PRPF40A	2.82e-04	170	20	3	M5657
Coexpression	GENTILE_UV_RESPONSE_CLUSTER_D5	SS18 NCOA3	3.24e-04	35	20	2	M13814
Coexpression	GSE37301_CD4_TCELL_VS_RAG2_KO_NK_CELL_DN	NCOA1 EMC3 KAT6A	3.33e-04	180	20	3	M8906
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	KAT6B NCOA1 NCOA3 KAT6A	3.81e-04	466	20	4	M13522
Coexpression	GSE19772_CTRL_VS_HCMV_INF_MONOCYTES_AND_PI3K_INHIBITION_UP	PRPF40A MLF2 CREB5	4.15e-04	194	20	3	M7288
Coexpression	GSE3982_DC_VS_NEUTROPHIL_LPS_STIM_DN	DCAF15 MLF2 CREB5	4.15e-04	194	20	3	M5393
Coexpression	GSE45382_UNTREATED_VS_TGFB_TREATED_MACROPHAGES_DN	BCL9L PRPF40A CREB5	4.21e-04	195	20	3	M9804
Coexpression	DESCARTES_ORGANOGENESIS_PREMATURE_OLIGODENDROCYTE	KAT6B CREB5	4.24e-04	40	20	2	MM3636
Coexpression	GSE26290_CTRL_VS_AKT_INHIBITOR_TREATED_ANTI_CD3_AND_IL2_STIM_CD8_TCELL_DN	NIPAL3 NCOA3 BCL9	4.34e-04	197	20	3	M8133
Coexpression	GSE360_L_DONOVANI_VS_T_GONDII_DC_DN	KAT6B PRPF40A MLF2	4.34e-04	197	20	3	M5196
Coexpression	GSE18281_SUBCAPSULAR_CORTICAL_REGION_VS_WHOLE_MEDULLA_THYMUS_UP	NCOA1 EP300 BCL9	4.47e-04	199	20	3	M7254
Coexpression	GSE17721_CTRL_VS_GARDIQUIMOD_0.5H_BMDC_DN	NCOA3 PRPF40A EMC3	4.47e-04	199	20	3	M3775
Coexpression	GSE22886_NAIVE_CD4_TCELL_VS_12H_ACT_TH2_UP	NIPAL3 KAT6B KAT6A	4.47e-04	199	20	3	M4526
Coexpression	GSE17322_CD103_POS_VS_CD11B_HIGH_LUNG_DC_DN	KAT6B SLC31A1 BCL9L	4.47e-04	199	20	3	M7390
Coexpression	GSE36527_CD69_NEG_VS_POS_TREG_CD62L_LOS_KLRG1_NEG_DN	RAB40C DCAF15 EMC3	4.53e-04	200	20	3	M9029
Coexpression	GSE41867_DAY6_EFFECTOR_VS_DAY30_MEMORY_CD8_TCELL_LCMV_ARMSTRONG_UP	NIPAL3 EP300 EMC3	4.53e-04	200	20	3	M9458
Coexpression	GSE24726_WT_VS_E2_2_KO_PDC_UP	NIPAL3 RAB40C NCOA3	4.53e-04	200	20	3	M8060
Coexpression	GSE31622_WT_VS_KLF3_KO_BCELL_UP	FOXA2 DCAF15 CELF4	4.53e-04	200	20	3	M8473
Coexpression	GSE21360_NAIVE_VS_QUATERNARY_MEMORY_CD8_TCELL_UP	NIPAL3 SLC31A1 NCOA3	4.53e-04	200	20	3	M7613
Coexpression	GSE21360_NAIVE_VS_QUATERNARY_MEMORY_CD8_TCELL_DN	NIPAL3 SLC31A1 NCOA3	4.53e-04	200	20	3	M7618
Coexpression	GSE17721_POLYIC_VS_CPG_12H_BMDC_UP	NCOA1 NCOA3 MLF2	4.53e-04	200	20	3	M3948
Coexpression	GSE16450_IMMATURE_VS_MATURE_NEURON_CELL_LINE_6H_IFNA_STIM_DN	SLC31A1 DCAF15 CREB5	4.53e-04	200	20	3	M7415
Coexpression	MURARO_PANCREAS_BETA_CELL	FOXA2 KAT6B NCOA3 CELF4 BCL9	5.98e-04	946	20	5	M39169
Coexpression	BENITEZ_GBM_PROTEASOME_INHIBITION_RESPONSE	MLF2 EP300	6.11e-04	48	20	2	M40000
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	KAT6B NCOA1 NCOA3 PRPF40A EP300 KAT6A	6.53e-04	1492	20	6	M40023
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-2m-Neuronal-Intermediate\|2m / Sample Type, Dataset, Time_group, and Cell type.	FOXA2 KAT6B CREB5 CELF4	1.74e-06	200	20	4	2a635694844ddabcd98462c5636a6f41a3f08a46
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NIPAL3 SLC31A1 DCAF15	4.38e-05	155	20	3	93f21b09f6f7755991d67886361b1c42a50fbbfc
ToppCell	TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Non-Papillary_Muscle_Invasive_Urothelial_Carcinoma-9\|TCGA-Bladder / Sample_Type by Project: Shred V9	BCL9L NCOA3 CLINT1	5.86e-05	171	20	3	adbcfa4bf6bc1c604535a24435924cdb091e2dd7
ToppCell	droplet-Marrow-nan-3m-Myeloid-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EP300 CLINT1 KAT6A	7.06e-05	182	20	3	f8c73baaaca145e2efc48f10f636feb79c8fc779
ToppCell	droplet-Marrow-nan-3m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EP300 CLINT1 KAT6A	7.29e-05	184	20	3	1154a5ad7b8512272b7476f949ddac350910bfb7
ToppCell	droplet-Marrow-nan-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EP300 CLINT1 KAT6A	7.41e-05	185	20	3	7adfa929930cfa795cbfbd9f1a0b439e08aa765d
Drug	anacardic acid	KAT6B NCOA1 EP300 KAT6A	1.17e-08	30	20	4	CID000167551
Drug	AC1L1COZ	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.28e-08	90	20	5	CID000001996
Drug	TiNi	KAT6B SLC31A1 NCOA3 EP300 KAT6A	2.17e-08	100	20	5	CID000159408
Drug	AC1L1G5B	KAT6B NCOA1 EP300 KAT6A	6.90e-08	46	20	4	CID000003531
Drug	glutamin	KAT6B NCOA1 NCOA3 PRPF40A MLF2 EP300 KAT6A	8.23e-08	461	20	7	CID000000738
Drug	vorinostat	KAT6B NCOA1 NCOA3 PRPF40A EP300 KAT6A	2.16e-07	314	20	6	CID000005311
Drug	In-G	KAT6B NCOA1 NCOA3 EP300 KAT6A	3.10e-07	170	20	5	CID000446054
Drug	CV-1	SS18 NCOA1 NCOA3 EP300 CREB5	9.45e-07	213	20	5	CID000130105
Drug	melatonin	KAT6B NCOA1 NCOA3 PRPF40A EP300 KAT6A	1.61e-06	443	20	6	CID000000896
Drug	AC1L2E0P	KAT6B NCOA1 NCOA3 EP300 KAT6A	5.67e-06	307	20	5	CID000019390
Drug	butamben	NCOA1 NCOA3	1.10e-05	6	20	2	ctd:C004605
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B SS18 DCAF15 EP300	1.42e-05	173	20	4	4237_DN
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	FOXA2 SS18 NCOA1 DCAF15	1.55e-05	177	20	4	4652_DN
Drug	AC1Q68Z5	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.72e-05	386	20	5	CID000000181
Drug	AC1N0FHX	EP300 KAT6A	2.05e-05	8	20	2	CID003916227
Drug	AC1LCVO8	KAT6B KAT6A	2.05e-05	8	20	2	CID000656891
Drug	Hydrochlorothiazide [58-93-5]; Down 200; 13.4uM; PC3; HT_HG-U133A	NIPAL3 SS18 NCOA3 CREB5	2.18e-05	193	20	4	6625_DN
Drug	MS-275; Down 200; 10uM; PC3; HT_HG-U133A	KAT6B NCOA1 EP300 CLINT1	2.18e-05	193	20	4	7084_DN
Drug	Althiazide [5588-16-9]; Down 200; 10.4uM; HL60; HT_HG-U133A	NIPAL3 SS18 NCOA3 DCAF15	2.23e-05	194	20	4	2527_DN
Drug	17-DMAG; Down 200; 0.1uM; HL60; HT_HG-U133A	KAT6B NCOA1 DCAF15 KAT6A	2.27e-05	195	20	4	6172_DN
Drug	Mevalonic-D, L acid lactone [674-26-0]; Down 200; 30.8uM; HL60; HT_HG-U133A	KAT6B SS18 DCAF15 CLINT1	2.32e-05	196	20	4	2718_DN
Drug	Orlistat; Down 200; 10uM; MCF7; HT_HG-U133A	SS18 NCOA3 MLF2 BCL9	2.32e-05	196	20	4	6905_DN
Drug	Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; HL60; HT_HG-U133A	KAT6B SS18 NCOA1 NCOA3	2.32e-05	196	20	4	1326_UP
Drug	Trichlorfon [52-68-6]; Down 200; 15.6uM; PC3; HT_HG-U133A	FOXA2 KAT6B SS18 NCOA3	2.41e-05	198	20	4	1797_DN
Drug	galangin	NCOA1 NCOA3 EP300	2.80e-05	68	20	3	ctd:C037032
Drug	CoA group	KAT6B NCOA1 NCOA3 EP300 KAT6A	2.98e-05	433	20	5	CID000000317
Drug	2,3,4,7,8-pentachlorodibenzofuran	NCOA1 NCOA3 EP300	3.76e-05	75	20	3	ctd:C038890
Drug	A25618	KAT6B NCOA1 NCOA3 EP300 CREB5 KAT6A	3.98e-05	777	20	6	CID000005562
Drug	2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	NCOA1 NCOA3	4.01e-05	11	20	2	ctd:C061137
Drug	C04424	KAT6B KAT6A	4.01e-05	11	20	2	CID011953835
Drug	B on A	KAT6B NCOA1 NCOA3 EP300 KAT6A	4.14e-05	464	20	5	CID000007104
Drug	C05118	KAT6B KAT6A	4.81e-05	12	20	2	CID000440565
Drug	C05119	KAT6B KAT6A	4.81e-05	12	20	2	CID000440566
Drug	dihydroxy-vitamin D3	NCOA1 NCOA3	5.68e-05	13	20	2	ctd:C118756
Drug	AC1L9EUB	KAT6B KAT6A	5.68e-05	13	20	2	CID000443527
Drug	AC1L9EU8	KAT6B KAT6A	6.63e-05	14	20	2	CID000443526
Drug	AC1LCVO5	KAT6B KAT6A	6.63e-05	14	20	2	CID000656890
Drug	ferutinin	NCOA1 NCOA3	8.73e-05	16	20	2	CID000354654
Drug	AC1L9ASI	KAT6B KAT6A	9.89e-05	17	20	2	CID000441230
Drug	AC1L9DEH	KAT6B NCOA1 NCOA3 EP300 KAT6A	1.09e-04	569	20	5	CID000442783
Drug	mobs	NCOA1 EP300	1.68e-04	22	20	2	CID003674064
Drug	sodium butyrate	KAT6B NCOA1 EP300 KAT6A	2.05e-04	344	20	4	CID005222465
Drug	Dihydrotestosterone	FOXA2 NCOA1 NCOA3 EP300	2.44e-04	360	20	4	ctd:D013196
Drug	LY117018	NCOA1 NCOA3	2.93e-04	29	20	2	CID000104946
Drug	tetrac	NCOA1 EP300	2.93e-04	29	20	2	CID000065552
Drug	3-hydroxyflavone	NCOA1 NCOA3	2.93e-04	29	20	2	ctd:C041477
Drug	Lycorine hydrochloride [2188-68-3]; Up 200; 12.4uM; HL60; HT_HG-U133A	NCOA3 DCAF15 CREB5	3.12e-04	153	20	3	2195_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	FOXA2 KAT6B DCAF15	4.25e-04	170	20	3	3791_DN
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	KAT6B NCOA1 NCOA3	4.32e-04	171	20	3	7535_DN
Drug	khellin	KAT6B NCOA3 KAT6A	4.32e-04	171	20	3	CID000003828
Drug	butyrate	KAT6B NCOA1 NCOA3 EP300 KAT6A	4.36e-04	767	20	5	CID000000264
Drug	L-165041	NCOA1 EP300	4.54e-04	36	20	2	CID006603901
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B DCAF15 EP300	4.54e-04	174	20	3	5745_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B SS18 EP300	4.54e-04	174	20	3	5065_DN
Drug	2-methylbutyryl-CoA	KAT6B KAT6A	4.79e-04	37	20	2	CID000000054
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B SS18 EP300	4.86e-04	178	20	3	4184_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B DCAF15 EP300	4.94e-04	179	20	3	6609_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	KAT6B NCOA3 PRPF40A	4.94e-04	179	20	3	4585_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B DCAF15 EP300	5.02e-04	180	20	3	3688_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	KAT6B EP300 KAT6A	5.02e-04	180	20	3	4541_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	KAT6B DCAF15 EP300	5.02e-04	180	20	3	6886_DN
Drug	cystamine	NCOA1 PRPF40A EP300	5.10e-04	181	20	3	CID000002915
Drug	Picrotoxinin [17617-45-7]; Down 200; 13.6uM; HL60; HT_HG-U133A	SS18 NCOA3 CLINT1	5.70e-04	188	20	3	2161_DN
Drug	Neostigmine bromide [114-80-7]; Down 200; 13.2uM; PC3; HT_HG-U133A	KAT6B NCOA3 PRPF40A	5.70e-04	188	20	3	6735_DN
Drug	MS-275; Down 200; 10uM; PC3; HT_HG-U133A	KAT6B DCAF15 CLINT1	5.78e-04	189	20	3	7074_DN
Drug	Nocodazole [31430-18-9]; Down 200; 13.2uM; PC3; HT_HG-U133A	SS18 NCOA3 KAT6A	5.87e-04	190	20	3	7145_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	KAT6B SS18 DCAF15	5.87e-04	190	20	3	6709_DN
Drug	Deptropine citrate [2169-75-7]; Down 200; 7.6uM; HL60; HT_HG-U133A	SS18 NCOA3 CLINT1	5.87e-04	190	20	3	3144_DN
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; PC3; HT_HG-U133A	FOXA2 SS18 DCAF15	5.96e-04	191	20	3	6721_DN
Drug	Monobenzone [103-16-2]; Down 200; 20uM; PC3; HT_HG-U133A	SS18 DCAF15 CLINT1	6.05e-04	192	20	3	6713_DN
Drug	Benfluorex hydrochloride [23642-66-2]; Down 200; 10.4uM; HL60; HT_HG-U133A	KAT6B SS18 CLINT1	6.05e-04	192	20	3	1266_DN
Drug	Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	KAT6B CLINT1 KAT6A	6.15e-04	193	20	3	4846_DN
Drug	Tropicamide [1508-75-4]; Down 200; 14uM; PC3; HT_HG-U133A	NIPAL3 FOXA2 KAT6A	6.15e-04	193	20	3	4280_DN
Drug	GSK-3beta Inhibitor VIII; Up 200; 10uM; PC3; HT_HG-U133A	SS18 NCOA3 CLINT1	6.15e-04	193	20	3	7097_UP
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; HL60; HT_HG-U133A	KAT6B SS18 NCOA3	6.15e-04	193	20	3	2477_DN
Drug	paclitaxel; Down 200; 0.1uM; MCF7; HG-U133A	NCOA1 EP300 BCL9	6.24e-04	194	20	3	640_DN
Drug	Enalapril maleate [76095-16-4]; Down 200; 8.2uM; HL60; HT_HG-U133A	KAT6B NCOA1 NCOA3	6.24e-04	194	20	3	2397_DN
Drug	Betazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A	NIPAL3 EP300 BCL9	6.24e-04	194	20	3	1812_UP
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; HL60; HG-U133A	KAT6B PRPF40A MLF2	6.24e-04	194	20	3	1988_DN
Drug	Moroxidine hydrochloride [3160-91-6]; Down 200; 19.2uM; PC3; HT_HG-U133A	SS18 DCAF15 KAT6A	6.24e-04	194	20	3	6705_DN
Drug	Methylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; PC3; HT_HG-U133A	FOXA2 EP300 BCL9	6.24e-04	194	20	3	7137_DN
Drug	11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	KAT6B SS18 KAT6A	6.24e-04	194	20	3	7538_DN
Drug	Kaempferol [520-18-3]; Down 200; 14uM; MCF7; HT_HG-U133A	KAT6B NCOA1 DCAF15	6.24e-04	194	20	3	7196_DN
Drug	Mebendazole [31431-39-7]; Down 200; 13.6uM; PC3; HT_HG-U133A	NIPAL3 SS18 BCL9	6.24e-04	194	20	3	3671_DN
Drug	Bufexamac [2438-72-4]; Up 200; 18uM; HL60; HT_HG-U133A	SS18 NCOA3 DCAF15	6.33e-04	195	20	3	2382_UP
Drug	Atractyloside potassium salt [102130-43-8]; Down 200; 5uM; PC3; HT_HG-U133A	SS18 NCOA3 CREB5	6.33e-04	195	20	3	3695_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A	KAT6B NCOA3 PRPF40A	6.33e-04	195	20	3	1785_DN
Drug	Tiaprofenic acid [33005-95-7]; Down 200; 15.4uM; MCF7; HT_HG-U133A	DCAF15 EP300 BCL9	6.33e-04	195	20	3	2852_DN
Drug	Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; MCF7; HT_HG-U133A	SS18 NCOA1 EP300	6.33e-04	195	20	3	5318_DN
Drug	Cisapride [81098-60-4]; Down 200; 8.6uM; PC3; HT_HG-U133A	SS18 DCAF15 CLINT1	6.33e-04	195	20	3	6706_DN
Drug	trichostatin A; Up 200; 0.1uM; HL60; HG-U133A	NIPAL3 NCOA1 NCOA3	6.33e-04	195	20	3	364_UP
Drug	Benfluorex hydrochloride [23642-66-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A	KAT6B SS18 DCAF15	6.33e-04	195	20	3	5327_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	NCOA1 EP300 BCL9	6.33e-04	195	20	3	7385_DN
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT_HG-U133A	SS18 NCOA1 NCOA3	6.33e-04	195	20	3	1156_UP
Drug	Pimethixene maleate [13187-06-9]; Down 200; 9.8uM; MCF7; HT_HG-U133A	KAT6B NCOA1 DCAF15	6.33e-04	195	20	3	7426_DN
Drug	Metrizamide [31112-62-6]; Up 200; 5uM; HL60; HT_HG-U133A	KAT6B SS18 NCOA3	6.33e-04	195	20	3	1318_UP
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A	SS18 NCOA1 BCL9	6.43e-04	196	20	3	3422_DN
Drug	Flurandrenolide [1524-88-5]; Down 200; 9.2uM; PC3; HT_HG-U133A	NIPAL3 FOXA2 SS18	6.43e-04	196	20	3	3679_DN
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; PC3; HT_HG-U133A	SS18 NCOA3 DCAF15	6.43e-04	196	20	3	3673_DN
Drug	Proxyphylline [603-00-9]; Up 200; 16.8uM; HL60; HT_HG-U133A	SS18 DCAF15 CREB5	6.43e-04	196	20	3	3115_UP
Disease	Prostatic Neoplasms	NIPAL3 SLC31A1 NCOA1 NCOA3 KAT6A ZIC2	2.44e-06	616	20	6	C0033578
Disease	Malignant neoplasm of prostate	NIPAL3 SLC31A1 NCOA1 NCOA3 KAT6A ZIC2	2.44e-06	616	20	6	C0376358
Disease	breast carcinoma (is_marker_for)	NCOA1 NCOA3 EP300	1.19e-05	66	20	3	DOID:3459 (is_marker_for)
Disease	prostate cancer (is_marker_for)	NCOA1 NCOA3 EP300	1.55e-04	156	20	3	DOID:10283 (is_marker_for)
Disease	left ventricular structural measurement	KAT6B SS18	1.61e-03	88	20	2	EFO_0008205
Disease	Adenoid Cystic Carcinoma	EP300 KAT6A	2.08e-03	100	20	2	C0010606
Disease	Squamous cell carcinoma	NCOA3 EP300	3.17e-03	124	20	2	C0007137
Disease	mood instability measurement	EP300 CELF4	3.37e-03	128	20	2	EFO_0008475
Disease	irritable bowel syndrome	EP300 CELF4	3.53e-03	131	20	2	EFO_0000555
Disease	Mammary Neoplasms, Human	NCOA1 NCOA3 EP300	5.10e-03	525	20	3	C1257931
Disease	Mammary Carcinoma, Human	NCOA1 NCOA3 EP300	5.10e-03	525	20	3	C4704874
Disease	Mammary Neoplasms	NCOA1 NCOA3 EP300	5.15e-03	527	20	3	C1458155
Disease	Malignant neoplasm of breast	KAT6B NCOA1 NCOA3 EP300	5.30e-03	1074	20	4	C0006142
Disease	Breast Carcinoma	NCOA1 NCOA3 EP300	5.45e-03	538	20	3	C0678222
Disease	anxiety	CREB5 CELF4	9.88e-03	223	20	2	EFO_0005230
Disease	neutrophil count, basophil count	NCOA1 CREB5	9.96e-03	224	20	2	EFO_0004833, EFO_0005090

Protein segments in the cluster

Peptide	Gene	Start	Entry
RMQHHMQQMQQGNMG	EP300	2226	Q09472
SMANGMNAVMMHGRS	RAB40C	226	Q96S21
MQMQMGMMGTQPYAQ	KAT6B	2021	Q8WYB5
AMSNGNMNTMGHMME	CREB5	246	Q02930
NMNTMGHMMEMMGSR	CREB5	251	Q02930
MDAMPGMQNMHDKGM	NIPAL3	336	Q6P499
LGNTPMMNQSMMGMN	CLINT1	566	Q14677
MMNQSMMGMNMNIGM	CLINT1	571	Q14677
MMGMNMNIGMSAAGM	CLINT1	576	Q14677
SVMPGMMMSHMSQAS	PRPF40A	106	O75400
MMMSHMSQASMQPAL	PRPF40A	111	O75400
TAQYPMQMQMGMMGS	KAT6A	1946	Q92794
MQMQMGMMGSQAYTQ	KAT6A	1951	Q92794
MMSMQGMMGPQQNIM	BCL9	1381	O00512
GMGQSMEMERMMQAH	BCL9L	701	Q86UU0
SRMMQEQMTGAAMAM	EMC3	196	Q9P0I2
HSHGGGDSSMMMMPM	SLC31A1	31	O15431
SANGMLMNMMMMSDE	DCAF15	161	Q66K64
FMDMFGMMNDMIGNM	MLF2	76	Q15773
GMMNDMIGNMEHMTA	MLF2	81	Q15773
GMNGMNTYMSMSAAA	FOXA2	36	Q9Y261
MNPMMAQMQMSSLQM	NCOA1	1331	Q15788
SMVHMNGSSGHMGQM	NCOA3	1391	Q9Y6Q9
HMGQMNMNPMPMSGM	NCOA3	1401	Q9Y6Q9
MQQMAGQMGMFNPMA	CELF4	241	Q9BZC1
PMGMMGQVNQGNHMM	SS18	231	Q15532
HNQYGPMNMNMGMNM	ZIC2	211	O95409
PMNMNMGMNMAAAAA	ZIC2	216	O95409